Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $485.0 to $510.0 for Vertex Pharmaceuticals over the last 3 months. High-rolling investors have positioned themselves bearish on Vertex Pharmaceuticals (NASDAQ:VRTX), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VRTX often signals that someone has privileged information.
高風險投資者在福泰製藥（納斯達克:VRTX）上看淡，對於零售交易者來說很重要。\通過Benzinga追蹤公開可獲得的期權數據發現了這一活動。這些投資者的身份尚不確定，但VRTX出現如此重要的變動通常意味着有人掌握了內幕消息。
Today, Benzinga's options scanner spotted 12 options trades for Vertex Pharmaceuticals. This is not a typical pattern.
今天，Benzinga的期權掃描器發現了福泰製藥的12筆期權交易。這不是典型的模式。
The sentiment among these major traders is split, with 8% bullish and 83% bearish. Among all the options we identified, there was one put, amounting to $55,692, and 11 calls, totaling $435,054.
這些主要交易者之間的情緒分歧，看漲8%，看跌83%。在所有確定的期權中，有一個看跌，金額爲$55,692，和11個看漲，總額爲$435,054。
What's The Price Target?
目標價是多少？
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $485.0 to $510.0 for Vertex Pharmaceuticals over the last 3 months.
考慮到這些合約的成交量和未平倉合約數量，似乎鯨魚們在過去3個月裏一直瞄準福泰製藥的價格範圍在$485.0到$510.0之間。
Volume & Open Interest Trends
成交量和未平倉量趨勢
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $485.0 to $510.0 in the last 30 days.
觀察成交量和未平倉合約的變化對交易期權是非常有用的一步。這些數據可以幫助你追蹤福泰製藥特定行權價格的期權的流動性和興趣。下面，我們可以看到在過去30天裏，地區內所有福泰製藥鯨魚交易的看漲和看跌的成交量和未平倉合約的變化。
Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview
福泰製藥看漲和看跌成交量：30天綜述
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | PUT | SWEEP | NEUTRAL | 08/30/24 | $4.4 | $4.3 | $4.4 | $485.00 | $55.6K | 10 | 150 |
| VRTX | CALL | SWEEP | BEARISH | 01/17/25 | $24.8 | $24.0 | $24.0 | $510.00 | $48.0K | 118 | 138 |
| VRTX | CALL | SWEEP | BEARISH | 01/17/25 | $24.4 | $23.7 | $23.8 | $510.00 | $47.4K | 118 | 2 |
| VRTX | CALL | TRADE | BEARISH | 01/17/25 | $25.1 | $24.3 | $24.5 | $510.00 | $44.1K | 118 | 250 |
| VRTX | CALL | TRADE | BEARISH | 01/17/25 | $24.8 | $24.1 | $24.1 | $510.00 | $43.3K | 118 | 156 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 福泰製藥 | 看跌 | SWEEP | 中立 | 08/30/2024 | $4.4 | $4.3 | $4.4 | 485.00美元 | $55.6K | 10 | 150 |
| 福泰製藥 | 看漲 | SWEEP | 看淡 | 01/17/25 | $24.8 | $24.0 | $24.0 | $510.00 | $48.0千 | 118 | 138 |
| 福泰製藥 | 看漲 | SWEEP | 看淡 | 01/17/25 | $24.4 | $23.7 | $23.8 | $510.00 | $47.4K | 118 | 2 |
| 福泰製藥 | 看漲 | 交易 | 看淡 | 01/17/25 | $25.1 | $24.3 | $24.5 | $510.00 | $44.1K | 118 | 250 |
| 福泰製藥 | 看漲 | 交易 | 看淡 | 01/17/25 | $24.8 | $24.1 | $24.1 | $510.00 | $43.3K | 118 | 156 |
About Vertex Pharmaceuticals
關於Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Vertex Pharmaceuticals是一家全球性生物技術公司，致力於發現和開發治療嚴重疾病的小分子藥物。其主要藥物是Kalydeco、Orkambi、Symdeko和Trikafta/Kaftrio，用於囊性纖維化，其中Vertex的治療法在全球範圍內仍是標準的護理。Vertex通過Casgevy進行了組合基因編輯治療β地中海貧血和鐮狀細胞病。此外，Vertex正在評估使用非阿片類治療的小分子抑制劑，以及針對APOL1介導的腎臟疾病的小分子抑制劑。Vertex還正在研究細胞療法，爲1型糖尿病提供潛在的功能性治癒。
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
在我們分析了與福泰製藥相關的期權活動之後，我們轉向更仔細地觀察公司的表現。
Present Market Standing of Vertex Pharmaceuticals
- With a volume of 284,458, the price of VRTX is up 0.65% at $482.99.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 73 days.
- RSI指標暗示該標的股票目前處於超買和超賣的中立區間。
- 下一個業績將在73天內發佈。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。
